Eli Lilly and Company Reports New Director Election
Summary
Eli Lilly and Company's Board of Directors elected Carolyn R. Bertozzi, Ph.D. as a new member on November 18, 2025, with an effective date of December 8, 2025. Dr. Bertozzi, 59, is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. She will serve on the Board's Science and Technology Committee and the Ethics and Compliance Committee. The Board determined Dr. Bertozzi is independent under applicable standards.
Why It Matters
The appointment of Dr. Bertozzi, an independent director with a strong scientific background, to the Board and its Science and Technology and Ethics and Compliance Committees enhances the company's governance and strategic oversight in critical areas.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how LLY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View LLY Charts on TradingViewAffiliate link
Key Quote
“On November 18, 2025, the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
— From Item 5.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000059478
- Filing Date
- Friday, November 21, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral